2018
The optimal timing of hepatitis C therapy in liver transplant‐eligible patients: Cost‐effectiveness analysis of new opportunities
Cortesi P, Belli L, Facchetti R, Mazzarelli C, Perricone G, De Nicola S, Cesana G, Duvoux C, Mantovani L, Strazzabosco M, Association T. The optimal timing of hepatitis C therapy in liver transplant‐eligible patients: Cost‐effectiveness analysis of new opportunities. Journal Of Viral Hepatitis 2018, 25: 791-801. PMID: 29406608, DOI: 10.1111/jvh.12877.Peer-Reviewed Original ResearchConceptsHepatocellular carcinomaDCC patientsTreatment strategiesIntestine Transplant AssociationProgression of HCVTransplant-eligible patientsHepatitis C therapyTransplant-related factorsCohort of patientsTime of transplantationDecision analytical modelCost-effectiveness analysisDAA effectivenessDAA treatmentEuropean LiverHCC presencePre-LTMELD scoreC therapyCirrhotic patientsDisease recurrenceTransplant centersSpecific regimenTransplant AssociationPatient level
2008
PA.191 COMBINED ANTIVIRAL THERAPY(PEG-IFN +RIBAVIRINE) IN RECURRENT HEPATITIS C AFTER LIVER TRANSPLANTATION. AN ITALIAN EXPERIENCE OF TWO TRANSPLANT CENTRES
Viganò R, Carderi I, Pasulo L, Colpani M, Boninsegna S, Burra P, Colledan M, Cillo U, Strazzabosco M, Fagiuoli S. PA.191 COMBINED ANTIVIRAL THERAPY(PEG-IFN +RIBAVIRINE) IN RECURRENT HEPATITIS C AFTER LIVER TRANSPLANTATION. AN ITALIAN EXPERIENCE OF TWO TRANSPLANT CENTRES. Digestive And Liver Disease 2008, 40: s145-s146. DOI: 10.1016/s1590-8658(08)60386-2.Peer-Reviewed Original Research